Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

03 Aug 2026, 12:50 UTC · 1h ago

Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Supernus Pharmaceuticals reported quarterly revenues of $219.06 million, beating the Zacks Consensus Estimate by 6.84%. — Revenue beats are generally positive signals for growth and operational health, though the magnitude here is moderate.
+0.30
2
Supernus Pharmaceuticals' year-over-year quarterly earnings declined to $0.54 per share from $0.91 per share. — A significant decline in year-over-year earnings suggests a contraction in profitability.
-0.20
3
Supernus Pharmaceuticals reported quarterly earnings of $0.54 per share, meeting the Zacks Consensus Estimate. — Earnings that exactly meet expectations typically result in neutral market movement as the data was already priced in.
+0.00
4